Comparison · NCT02556788-ce23949c
CD5789 (Trifarotene) 50µg/g Cream vs Placebo Cream: Investigator Global Assessment (IGA) Score of 1 (Almost Clear) or 0 (Clear)
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. CD5789 (Trifarotene) 50µg/g Cream vs Placebo Cream: Investigator Global Assessment (IGA) Score of 1 (Almost Clear) or 0 (Clear). Trial comparisons, record NCT02556788-ce23949c. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02556788-ce23949c
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.426 | 0.387 | 0.466 | wilson | |
| Risk in group 2 | 0.258 | 0.225 | 0.294 | wilson | |
| Risk difference, group 1 minus group 2 | 0.169 | 0.115 | 0.221 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.65 | 1.4 | 1.95 | log | |
| Odds ratio, group 1 over group 2 | 2.14 | 1.68 | 2.73 | log | |
| Number needed to treat, for one more participant with the outcome on CD5789 (Trifarotene) 50µg/g Cream than on Placebo Cream | 5.93 | 4.53 | 8.67 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | CD5789 (Trifarotene) 50µg/g Cream | CD5789 (Trifarotene) 50µg/g cream applied once daily during 12 weeks. | 255 | 598 | OG000 |
| Group 2 | Placebo Cream | Placebo cream applied once daily during 12 weeks. | 157 | 609 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- PRIMARY
- Title
- Investigator Global Assessment (IGA) Score of 1 (Almost Clear) or 0 (Clear)
- Description
- Number of subjects who achieved an Investigator Global Assessment (IGA) score of 1 (almost clear) or 0 (Clear) and at least a 2-grade improvement from Baseline to Week 12.
- Time frame
- From Baseline to Week 12
- Population
Source ClinicalTrials.gov
Trial
- Title
- Double-Blind Efficacy and Safety of CD5789 (Trifarotene) 50µg/g Cream Versus Vehicle Cream in Acne Vulgaris
- NCT number
- NCT02556788
- Phases
- PHASE3
- Conditions
- Acne Vulgaris
- Interventions
- CD5789 (trifarotene) 50µg/g Cream, Placebo Cream
- Lead sponsor
- Galderma R&D
- Results first posted
- 2019-09-03
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02556788?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02556788-ce23949c